Ahlstrom announces FDA Class 1 listing for its innovative biological sample collection cards
AHLSTROM OYJ, PRESS RELEASE, FEBRUARY 20, 2025 at 11 EET
Ahlstrom, a global leader in fiber-based specialty materials, is proud to announce that its biological sample collection cards have been officially listed as FDA Class 1 medical devices. This classification by the US Food and Drug Administration (FDA) affirms the safety, reliability, and compliance of GenSaver™ 2.0, GenSaver™ Color 2.0., AutoCollect™, 5 circles, BioSample, HemaSep™ Strip, HemaSep™ Punch and Lipid Saver™ sample collection cards with the highest industry standards.
These products are designed for the secure and efficient collection, transportation, and ambient-temperature storage of biological samples. They provide researchers, healthcare professionals, and forensic experts with a high-quality solution for sample integrity and analysis, and overall address the global trend for quality, personalized healthcare.
The FDA Class 1 listing is particularly important for biological sample collection cards as it ensures the products meet essential regulatory requirements for safety and effectiveness. This designation confirms that the cards are manufactured under stringent quality control processes. The FDA Class 1 listing further solidifies Ahlstrom’s commitment to delivering regulatory-compliant, high-performance products to the medical and scientific communities worldwide. The listing facilitates broader adoption by institutions requiring FDA-listed devices for compliance with industry standards and enhances global market access.
“We are pleased to have achieved the FDA Class 1 listing for our biological sample collection cards,” said Tamara Quatrano, Vice President, Lab & Life Science business at Ahlstrom. “This milestone underscores our dedication to providing cutting-edge solutions that meet rigorous safety and quality standards while addressing the global trend of quality, personalized healthcare with our technology. Our customers can confidently use our products knowing they comply with FDA regulations.”
Ahlstrom’s collection cards are ideal for use in critical applications, including diagnostic testing, genetic research, forensic analysis, epidemiological studies, and biobanking. With this FDA listing, Ahlstrom is poised to expand its reach and provide even greater value to industries that rely on accurate and secure sample collection.
For more information, please contact:
Tonia Showers, Head of Sales Americas, Lab & Life Science, tonia.showers@ahlstrom.com
To learn more about Ahlstrom range of Biological Sample Collection Cards visit: https://www.ahlstrom.com/products/medical-life-sciences-and-laboratory/specimen-collection-cards/
Ahlstrom in brief
Ahlstrom is a global leader in combining fibers into sustainable specialty materials. Our purpose is to Purify and Protect, with Every Fiber, for a Sustainable World. Our vision is to be the Preferred Sustainable Specialty Materials Company for all our stakeholders. Our three divisions, Filtration and Life Sciences, Food and Consumer Packaging, and Protective Materials, address global trends with safe and sustainable solutions. Our net sales in 2023 amounted to EUR 3.0 billion and we employ some 7,000 people. Read more: www.ahlstrom.com.